Literature DB >> 25043633

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Anne-Sophie Dugast1, Leonidas Stamatatos, Andrew Tonelli, Todd J Suscovich, Anna F Licht, Iliyana Mikell, Margaret E Ackerman, Hendrik Streeck, P J Klasse, John P Moore, Galit Alter.   

Abstract

Fc-related antibody activities, such as antibody-dependent cellular cytotoxicity (ADCC), or more broadly, antibody-mediated cellular viral inhibition (ADCVI), play a role in curbing early SIV viral replication, are enriched in human long-term infected nonprogressors, and could potentially contribute to protection from infection. However, little is known about the mechanism by which such humoral immune responses are naturally induced following infection. Here, we focused on the early evolution of the functional antibody response, largely driven by the Fc portion of the antibody, in the context of the evolving binding and neutralizing antibody response, which is driven mainly by the antibody-binding fragment (Fab). We show that ADCVI/ADCC-inducing responses in humans are rapidly generated following acute HIV-1 infection, peak at approximately 6 months postinfection, but decay rapidly in the setting of persistent immune activation, as Fab-related activities persistently increase. Moreover, the loss of Fc activity occurred in synchrony with a loss of HIV-specific IgG3 responses. Our data strongly suggest that Fc- and Fab-related antibody functions are modulated in a distinct manner following acute HIV infection. Vaccination strategies intended to optimally induce both sets of antiviral antibody activities may, therefore, require a fine tuning of the inflammatory response.
© 2014 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  ADCC; Antibodies; HIV; IgG3

Mesh:

Substances:

Year:  2014        PMID: 25043633      PMCID: PMC4311770          DOI: 10.1002/eji.201344305

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  57 in total

1.  Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo.

Authors:  Markus Biburger; Susanne Aschermann; Inessa Schwab; Anja Lux; Heike Albert; Heike Danzer; Melissa Woigk; Diana Dudziak; Falk Nimmerjahn
Journal:  Immunity       Date:  2011-12-08       Impact factor: 31.745

Review 2.  Isotype and glycoform selection for antibody therapeutics.

Authors:  Roy Jefferis
Journal:  Arch Biochem Biophys       Date:  2012-03-23       Impact factor: 4.013

3.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection.

Authors:  Nicole L Yates; Judith T Lucas; Tracy L Nolen; Nathan A Vandergrift; Kelly A Soderberg; Kelly E Seaton; Thomas N Denny; Barton F Haynes; Myron S Cohen; Georgia D Tomaras
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

Review 4.  HIV-specific antibody immunity mediated through NK cells and monocytes.

Authors:  Marit Kramski; Matthew S Parsons; Ivan Stratov; Stephen J Kent
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

Review 5.  Impact of differential glycosylation on IgG activity.

Authors:  Anja Lux; Falk Nimmerjahn
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  Activation of NK cells by ADCC responses during early HIV infection.

Authors:  Amy W Chung; Marjon Navis; Gamze Isitman; Rob Centre; Robert Finlayson; Mark Bloch; Linda Gelgor; Antony Kelleher; Stephen J Kent; Ivan Stratov
Journal:  Viral Immunol       Date:  2011-04       Impact factor: 2.257

7.  Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Kramski; A Schorcht; A P R Johnston; G F Lichtfuss; S Jegaskanda; R De Rose; I Stratov; A D Kelleher; M A French; R J Center; A Jaworowski; S J Kent
Journal:  J Immunol Methods       Date:  2012-07-24       Impact factor: 2.303

8.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples.

Authors:  Eric P Brown; Anna F Licht; Anne-Sophie Dugast; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Immunol Methods       Date:  2012-09-27       Impact factor: 2.303

9.  Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.

Authors:  Mohammed Asmal; Yue Sun; Sophie Lane; Wendy Yeh; Stephen D Schmidt; John R Mascola; Norman L Letvin
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

10.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

View more
  34 in total

1.  Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.

Authors:  Caitlin Milligan; Barbra A Richardson; Grace John-Stewart; Ruth Nduati; Julie Overbaugh
Journal:  Cell Host Microbe       Date:  2015-04-08       Impact factor: 21.023

Review 2.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 3.  Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.

Authors:  Srivamshi Pittala; Kyle S Morrison; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

4.  Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.

Authors:  Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

Review 5.  Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.

Authors:  Austin W Boesch; Galit Alter; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

6.  Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.

Authors:  Marina R Alexander; Rogier W Sanders; John P Moore; Per Johan Klasse
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-20       Impact factor: 2.205

Review 7.  Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.

Authors:  David R Martinez; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

8.  Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

Authors:  Benjamin von Bredow; Juan F Arias; Lisa N Heyer; Brian Moldt; Khoa Le; James E Robinson; Susan Zolla-Pazner; Dennis R Burton; David T Evans
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  Assessment of the antiviral capacity of primary natural killer cells by optimized in vitro quantification of HIV-1 replication.

Authors:  Xuan He; Camille R Simoneau; Mitchell E Granoff; Sebastian Lunemann; Anne-Sophie Dugast; Yiming Shao; Marcus Altfeld; Christian Körner
Journal:  J Immunol Methods       Date:  2016-04-16       Impact factor: 2.303

10.  Fc functional antibodies in humans with severe H7N9 and seasonal influenza.

Authors:  Hillary A Vanderven; Lu Liu; Fernanda Ana-Sosa-Batiz; Thi Ho Nguyen; Yanmin Wan; Bruce Wines; P Mark Hogarth; Danielle Tilmanis; Arnold Reynaldi; Matthew S Parsons; Aeron C Hurt; Miles P Davenport; Tom Kotsimbos; Allen C Cheng; Katherine Kedzierska; Xiaoyan Zhang; Jianqing Xu; Stephen J Kent
Journal:  JCI Insight       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.